Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Window of Opportunity (WoO) Study Evaluating Pembrolizumab With or Without Olaparib in Tertiary Lymphoid Structures (TLS)-Positive Selected Resectable Soft Tissue Sarcoma (STS) Followed by Adjuvant Pembrolizumab

NCT06116578 is registered in ClinicalTrials.gov with Gustave Roussy, Cancer Campus, Grand Paris as lead sponsor.

NCT NCT06116578
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06116578 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Window of Opportunity (WoO) Study Evaluating Pembrolizumab With or Without Olaparib in Tertiary Lymphoid Structures (TLS)-Positive Selected Resectable Soft Tissue Sarcoma (STS) Followed by Adjuvant Pembrolizumab
Lead sponsor
Gustave Roussy, Cancer Campus, Grand Paris
Phase
Phase 2
Overall status
Withdrawn
Start date
January 1, 2025
Completion date
June 30, 2029
Enrollment
0 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

cancer